➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Medtronic
Mallinckrodt
Baxter
Colorcon

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

Litigation Details for Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC (D. Del. 2018)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC (D. Del. 2018)

Docket   Start Trial Date Filed 2018-12-19
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand None Referred To Christopher J. Burke
Parties AMNEAL PHARMACEUTICALS PVT. LTD.; FRESENIUS KABI USA, LLC
Patents 10,086,010; 6,264,981; 6,284,770; 6,316,023; 6,335,031; 6,414,016; 6,592,903; 6,602,911; 6,716,867; 6,720,001; 6,780,889; 6,967,028; 7,101,576; 7,262,219; 7,297,703; 7,410,651; 7,431,943; 7,566,462; 7,566,714; 7,601,758; 7,612,073; 7,619,004; 7,659,282; 7,668,730; 7,727,987; 7,741,338; 7,765,106; 7,765,107; 7,767,656; 7,795,312; 7,820,681; 7,833,546; 7,851,482; 7,851,506; 7,888,342; 7,895,059; 7,906,519; 7,915,269; 7,919,115; 7,932,241; 7,935,731; 7,951,400; 7,964,219; 7,964,647; 7,964,648; 7,981,938; 7,994,220; 8,003,126; 8,008,003; 8,008,006; 8,013,002; 8,017,150; 8,026,393; 8,039,009; 8,039,030; 8,052,987; 8,058,052; 8,062,667; 8,067,416; 8,071,613; 8,093,296; 8,093,297; 8,093,298; 8,097,653; 8,097,655; 8,114,383; 8,168,209; 8,173,708; 8,192,722; 8,227,484; 8,242,131; 8,252,809; 8,263,125; 8,263,650; 8,283,379; 8,287,888; 8,287,903; 8,293,273; 8,298,576; 8,298,580; 8,309,060; 8,309,122; 8,318,745; 8,324,189; 8,324,275; 8,329,216; 8,329,752; 8,338,639; 8,362,085; 8,389,542; 8,404,215; 8,415,395; 8,415,396; 8,450,338; 8,457,988; 8,465,765; 8,475,832; 8,481,083; 8,497,256; 8,501,730; 8,563,033; 8,589,182; 8,591,938; 8,592,480; 8,598,233; 8,603,514; 8,642,012; 8,663,683; 8,731,963; 8,772,306; 8,778,390; 8,784,888; 8,808,737; 8,859,619; 8,871,779; 8,877,248; 8,895,064; 8,920,817; 9,000,002; 9,000,011; 9,000,021; 9,000,041; 9,005,016; 9,022,022; 9,024,007; 9,028,005; 9,035,085; 9,061,003; 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223; RE41,148; RE42,096; RE43,797; RE43,799
Attorneys Robert M. Vrana; William O. Adams
Firms Farnan LLP; Law Office of Michael R. Abram
Link to Docket External link to docket

Details for Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-12-19 1 the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”) and 9,937,223 (“the ‘223… United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of the… The Patents-in-Suit 14. On June 28, 2016, the United States Patent and Trademark…copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. 15. External link to document
2020-07-09 156 Exhibit 1 14. United States Patent No. 9,375,478 (“the ’478 patent”) is titled “Vasopressin Formulations…face of United States Patent No. 9,744,209 (“the ’209 patent”), the ’209 patent issued on August 29,…face of United States Patent No. 9,750,785 (“the ’785 patent”), the ’785 patent issued on September …in the ’239 patent. See, e.g., id. 162. The ’223 patent, like the ’239 patent, claims a vasopressin…Invalidity of the ’785 patent) Each of the claims of the ’785 patent are invalid for failure External link to document
2020-07-09 157 Redacted Document . 14. United States Patent No. 9,375,478 (“the ’478 patent”) is titled “Vasopressin Formulations…face of United States Patent No. 9,744,209 (“the ’209 patent”), the ’209 patent issued on August 29, …face of United States Patent No. 9,750,785 (“the ’785 patent”), the ’785 patent issued on September 5… in the ’239 patent. See, e.g., id. 162. The ’223 patent, like the ’239 patent, claims a vasopressin…(Invalidity of the ’785 patent) Each of the claims of the ’785 patent are invalid for failure External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
AstraZeneca
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.